Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics
Srikanth Boinapally(Johns Hopkins University), Sangeeta Ray Banerjee(Techno India University), Gabriela Lofland(Morgan State University), Zirui Jiang(Morgan State University), Martin G. Pomper(Southwestern Medical Center), Yu Yan(Johns Hopkins University), Suresh Alati(Morgan State University), Robert F. Hobbs(Morgan State University), Alla Lisok(Morgan State University), Rajiv K. Singh(Johns Hopkins University), Il Minn(Southwestern Medical Center)
Cited by 21
Related Papers
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
|Cancer Cell|2012|652
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
|Biochemical and Biophysical Research Communications|2004|350
Amide proton transfer imaging of human brain tumors at 3T
|Magnetic Resonance in Medicine|2006|341
Future cancer research priorities in the USA: a Lancet Oncology Commission
|The Lancet Oncology|2017|209
<sup>18</sup>F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
|Journal of Nuclear Medicine|2015|198